Compare IRIX & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IRIX | PPCB |
|---|---|---|
| Founded | 1989 | 2007 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 20.4M |
| IPO Year | 1996 | N/A |
| Metric | IRIX | PPCB |
|---|---|---|
| Price | $0.94 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 98.9K | ★ 266.2K |
| Earning Date | 11-11-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,647,000.00 | N/A |
| Revenue This Year | $9.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.58 | N/A |
| 52 Week Low | $0.78 | $0.73 |
| 52 Week High | $1.89 | $145.46 |
| Indicator | IRIX | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 45.74 | N/A |
| Support Level | $0.91 | N/A |
| Resistance Level | $0.96 | N/A |
| Average True Range (ATR) | 0.04 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 46.52 | 0.00 |
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.